Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on GLP 1 Analogue. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Novel GLP-1 analogues with extended half-life via microwave solid-phase synthesis. Stable, high-purity pharmaceutical intermediates for diabetes treatment.
Patent CN102180963B details a novel GLP-1 analogue modified with 4-hydroxycoumarin for extended half-life. Discover cost-effective microwave solid-phase synthesis strategies for diabetes therapeutics.
Advanced GLP-1 analogue synthesis via solid-phase strategy. Enhances half-life and stability significantly. Reliable supply chain for diabetes treatment intermediates manufacturing.
Patent CN103087177A details microwave-assisted solid-phase synthesis of stable GLP-1 analogues with extended half-life, offering cost-effective manufacturing solutions.
Patent CN112125970A reveals a novel solid-phase synthesis for Semaglutide using specialized Asp protection and fragment condensation to enhance yield and purity for reliable API manufacturing.
Patent CN112028986A reveals a novel solid-phase method for semaglutide using dipeptide fragments to enhance purity and reduce industrial production costs.
Patent CN110845600B reveals a novel solid-phase strategy improving purity and yield for Liraglutide manufacturing, offering significant supply chain advantages.